May 21, 2024 06:10 GMT
Astra Zeneca: Bullish Note From Company
HEALTHCARE
Astra Zeneca {AZN: A2/A): Company Update
Astra Zeneca released a bullish note today in which they anticipate:
- Revenue of $80b annually by 2030 (up from $45b 2023)
- 20 new drugs delivered – many with $5bn Peak Year revenues.
- Growth coming from Oncology, BioPharma and Rare Disease portfolio.
Investor day link: {www.astrazeneca.com/investor-relations/astrazeneca-investor-day.html}
51 words